Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04974489 · ClinicalTrials.gov registry record · NA

Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes

A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
1,153
Enrollment target

NCT04974489: Completed NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT04974489 is a NA study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 1,153 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04974489, a NA study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
1,153 participants
Enrollment target

Study Summary

Tobacco use is the leading preventable cause of cancer and cancer deaths in the US. While most (69%) smokers want to quit, only 6% succeed in doing so each year. For many smokers, the addictiveness of nicotine makes quitting very difficult. To reduce cigarette smoking and resulting harms, FDA has announced a comprehensive approach to tobacco and nicotine regulation that includes moving toward a very low nicotine content (VLNC) standard for cigarettes. Greatly reduced nicotine levels would facilitate smoking cessation. However, the maximal success of the policy may require public understanding that, although these new cigarettes are less addictive, their high toxicity and carcinogenicity are unchanged. Yet, nearly half of adult smokers incorrectly think smoking VLNC cigarettes is less harmful than smoking current cigarettes (the VLNC misperception). Additionally, 24% of smokers said they would be less likely to quit if a VLNC regulation is enacted. Thus, the VLNC misperception may partially undermine a nicotine reduction policy. Although communication research suggests it is challenging to change people's incorrect understanding, new communication techniques may help reduce the VLNC misperception. In this randomized trial we will examine whether messages about the harm of VLNC cigarettes can reduce the VLNC misperception and increase intention to quit in a nicotine reduction scenario.

Primary Outcome

Measured by a 3 item scale. Very low nicotine content (VLNC) Misperception measured with 3 questions, the final VLNC misperception score is a mean of the response to the 3 questions, on a scale of 1 to 5, where 1 indicates a perception that VLNC are much more harmful than other cigarettes, and 5 indicates a perception that VLNC are much less harmful than other cigarettes, and 3 is a perception that VLNC are as harmful as other cigarettes.

Interventions

  • BEHAVIORAL Emotion-based messages about the harm of VLNC
  • BEHAVIORAL Continued-harm-framed messages about the harm of VLNC
  • BEHAVIORAL Myth-refuting messages about the harm of VLNC
  • BEHAVIORAL Control messages about littering

Trial Details

FieldValue
Enrollment Target 1,153 participants
Start Date 2021-07-01
Est. Completion 2021-08-03
Phase NA

What the finished NCT04974489 record still lists

NCT04974489 is an interventional study that assigns participants to a tested intervention. Its 1,153 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (18% lower).

The record links to 0 conditions, and to 4 interventions - of which Emotion-based messages about the harm of VLNC is the first listed.

NCT04974489 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04974489 about?

NCT04974489 is a clinical study titled "Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes". Tobacco use is the leading preventable cause of cancer and cancer deaths in the US. While most (69%) smokers want to quit, only 6% succeed in doing so each year. For many smokers, the addictiveness of nicotine makes quitting very difficult. To reduce cigarette smoking and resulting harms, FDA has an...

What is the current status of trial NCT04974489?

This trial is currently completed. It is a NA study. The enrollment target is 1,153 participants. The study started on 2021-07-01. Estimated completion is 2021-08-03.

What interventions are being tested in trial NCT04974489?

The interventions under investigation include: Emotion-based messages about the harm of VLNC (BEHAVIORAL), Continued-harm-framed messages about the harm of VLNC (BEHAVIORAL), Myth-refuting messages about the harm of VLNC (BEHAVIORAL), Control messages about littering (BEHAVIORAL).

Who is sponsoring clinical trial NCT04974489?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04974489's enrollment target sits among peer trials

1,153 92nd of 2000 higher than 1,909 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04474301 · 1,152 participants

    Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

  • NCT05564026 · 1,151 participants

    Molecular Epidemiology of Pediatric Germ Cell Tumors

  • NCT06408181 · 1,150 participants · Phase 3

    APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

  • NCT06528314 · 1,150 participants · Phase 3

    A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04974489, the US trial registry maintained by the National Library of Medicine. NCT04974489 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.